

October 1, 2021

Dear Dean Health Plan Provider:

Dean Health Plan's Medical Policy Committee has approved the drug policies highlighted in this notification. These changes, and other changes not included in this notification, will also be communicated in the quarterly provider newsletters and available online. Please share this information with others within your organization who may be affected by these changes.

Information in this notification is applicable to all Dean Health Plan products, unless specified.

Dean Health Plan requires providers to obtain prior authorization on all drugs with written policies by sending authorization requests to Navitus, unless otherwise noted in the policy. Please note that most drugs require specialists to prescribe and request authorization.

### **Changes to Drug Policies**

Effective for dates of service on and after January 1, 2022, the following will be changed:

- Medically Administered Oncology Products MB2112 — which are used for cancer treatment. Additional products added: Asparlas, Danyelza, Isotodax, Jevtana, Margenza, Pepaxto, Unituxin, Zynlonta, Oncaspar, Lumoxiti, and Polivy. Prior authorization is required and is restricted to oncology prescribers.
- Pegfilgrastim Products MB1808 — which is used to reduce the chance of infection in people who have certain types of cancer and are receiving chemotherapy medications that may decrease the number of neutrophils (a type of blood cell needed to fight infection). J Code update for Neulasta and Neulasta Onpro from J2505 to J2506. Prior authorization is required for Neulasta, Neulasta OnPro, Nyvepria, or Udenyca only. Prior authorization is not required for Fulphila, or Ziextenzo.
- PROLIA, XGEVA (denosumab) MB9409 — which is a RANK ligand (RANKL) inhibitor indicated for treatment of postmenopausal women with osteoporosis at high risk for fracture, treatment to increase bone mass in men with osteoporosis at high risk for fracture, treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture, treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer, and treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. Prior Authorization is required and is restricted to Oncology, Rheumatology, Internal Medicine, Family Medicine, Orthopedic Surgery, or Endocrinology prescribers.

### **Retired Policies**

Effective for January 1, 2022, the drug policies listed below will be retired, but not the drugs themselves. The policies for the following drugs will be included under the medical policy titled "Medically Administered Oncology Products," MB2112:

- ONCASPAR (pegasparagase) MB1903
- LUMOXITI (moxetumomab) MB1920
- POLIVY (polatuzumab vedotin-piiq) MB1938

### **Medical Benefit Drug Policies**

Prescribers are encouraged to track changes and review policies in their entirety. Medical benefit drug policies are accessible online via the Dean Health Plan Document Library at

[deancare.com/document-repository](https://deancare.com/document-repository) or by visiting [deancare.com](https://deancare.com) and following the step-by-step instructions below:

- Select the drop down from the **I AM A...** screen to **Provider**.
- Navigate to **Pharmacy Services**.
- Under **Up to date Drug Policies**, click **See library**.
- Enter the drug name or the numerical digits of the assigned policy number (e.g. entering 1234 of the medical benefit policy number MB1234) in the **Search for** field to find the full catalog of drug policies.

Criteria for pharmacy benefit medications may be found on the associated prior authorization form located in the Provider Portal.

Please email any questions to [DHPParmacyServices@deancare.com](mailto:DHPParmacyServices@deancare.com).

Sincerely,  
Dean Health Plan Pharmacy Services

This notification will be published on the Dean Health Plan Provider Communications web page at [deancare.com/providers/provider-communications](https://deancare.com/providers/provider-communications). Visit this page for on-demand access to current and past communications.